Dapagliflozin And Metformin Hydrochloride Tablet, Film Coated, Extended Release
FDA Label NDC 66993-361

57 label sections · Submitted to the FDA by Prasco Laboratories · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Prasco Laboratories for the product Dapagliflozin And Metformin Hydrochloride (NDC 66993-361). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: lactic acidosis, 1 indications and usage, 2.1 testing prior to initiation of dapagliflozin and metformin hcl extended-release tablets, 2.2 recommended administration, 2.3 recommended dosage, 2.4 recommended dosage in patients with renal impairment, 2.5 discontinuation for iodinated contrast imaging procedures, 2.6 temporary interruption for surgery, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.